Corticosteroids in Community Acquired Pneumonia

Summary

This is a single-center, blinded, placebo-controlled pilot RCT evaluating corticosteroids for the treatment of Community Acquired Pneumonia (CAP) that will enroll 100 adults hospitalized with community-acquired pneumonia. The primary goal is to assess the feasibility of proposed trial procedures for use in a subsequent phase III trial powered on 6-month cognitive outcome (MOCA-Blind score). Key outcomes are six-month cognitive and functional status, duration and severity of symptoms, and mortality.

Timeline

Start

2020-12-01

Primary completion

2022-07-30

Completion

2022-07-30

Outcome

Outcome not reported

Stopped (Enrollment): “Limited enrollment due to the COVID-19 pandemic. Sponsor withdrew funding.”

Drugs

Indications